サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1739100

デスモイド腫瘍の世界市場

Desmoid Tumors

出版日
ページ情報
英文 286 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
デスモイド腫瘍の世界市場
出版日: 2025年06月03日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 286 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

デスモイド腫瘍の世界市場は2030年までに80億米ドルに達する見込み

2024年に56億米ドルと推定されるデスモイド腫瘍の世界市場は、分析期間2024-2030年にCAGR 6.2%で成長し、2030年には80億米ドルに達すると予測されます。本レポートで分析したセグメントの一つである非ステロイド性抗炎症薬は、CAGR7.1%を記録し、分析期間終了時には30億米ドルに達すると予測されます。標的治療薬セグメントの成長率は、分析期間中CAGR 7.2%と推定されます。

米国市場は15億米ドルと推定、中国はCAGR 9.9％で成長予測

米国のデスモイド腫瘍市場は2024年に15億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.9%と6.0%と予測されています。欧州では、ドイツがCAGR 4.0%で成長すると予測されています。

世界のデスモイド腫瘍市場- 主要動向と促進要因のまとめ

希少腫瘍への注目の原動力は？デスモイド腫瘍市場の戦略的考察

進行性線維腫症としても知られるデスモイド腫瘍は、転移はないが局所浸潤性のまれな軟部組織腫瘍であり、予測不能な進行と解剖学的影響により複雑な臨床課題を呈します。歴史的に診断と治療が不十分であったこの疾患は、ゲノム・プロファイリングと標的治療の進歩により、製薬企業や臨床研究者の双方から新たな関心を集めています。市場を再形成する一つの大きな動向は、CTNNB1遺伝子とAPC遺伝子における変異の同定であり、これにより精密医療アプローチへの扉が開かれました。これらの遺伝子マーカーは、特にWnt/β-カテニンシグナル伝達経路阻害剤に対する治療反応性で患者を層別化することを可能にします。

もう一つの変革的動向は、治療の第一選択としての手術からのシフトです。多くのデスモイド腫瘍は自然に安定化または退縮するという新たなデータに支えられ、医師は"watchful waiting "戦略を採用することが増えています。介入が必要な場合には、チロシンキナーゼ阻害剤（例、ソラフェニブ）やガンマセクレターゼ阻害剤（例、ニロガセスタット）などの非外科的治療が有望な結果を示しています。米国FDAの希少疾病用医薬品（Orphan Drug Status）指定や、治験薬に対するファストトラック（Fast Track）指定は、この希少疾病領域へのバイオテクノロジー投資を引き寄せています。

なぜこの市場では治療方法の進化が重要なのか？

デスモイド腫瘍の治療パラダイムは、再発率や罹患率の高い従来の外科手術や放射線治療の限界によって急速に進化しています。新しい治療プロトコールでは、局所的な治療よりも全身的な治療が支持されています。ソラフェニブ、パゾパニブ、イマチニブなどの経口チロシンキナーゼ阻害薬（TKI）は、非侵襲的な投与と比較的良好な安全性プロファイルのために人気を集めています。これらの薬剤は血管新生と腫瘍増殖の経路を阻害し、切除不能な症例の進行を遅らせる効果が実証されています。

標的治療薬、特にガンマセクレターゼ阻害薬は、パイプラインの最先端分野です。SpringWorks Therapeuticsのニロガセスタットは、第III相試験で統計学的に有意な無増悪生存期間を示し、トップランナーとして浮上しました。これらの薬剤は、腫瘍増殖に関与するNotchシグナル伝達経路を直接阻害するため、標準治療を再定義する準備が整っています。一方、非ステロイド性抗炎症薬やタモキシフェンのようなホルモン療法は、特に全身療法に耐えられない場合に、選択的に使用され続けています。このような治療法の多様化は、デスモイド腫瘍患者の臨床的展望を変え、病期や患者層を超えて治療の選択肢を広げています。

需要はどこで生まれ、誰が主要利害関係者か？

デスモイド腫瘍市場は、診断インフラと希少疾患研究資金が最も充実している北米と西欧に主に集中しています。しかし、新興市場、特にアジア太平洋とラテンアメリカの都市部の病院システムにおける認知度の向上が、世界の状況を変え始めています。画像診断の改善、医師教育の向上、ゲノム検査へのアクセスが、腫瘍の早期発見とサブタイプの正確な分類に役立っています。

主な利害関係者には、学術研究機関、腫瘍に特化した製薬会社、希少疾患擁護団体、臨床試験ネットワークなどがあります。疫学的パターンや治療成績をよりよく理解するために、患者登録やバイオバンクの取り組みが拡大しています。デスモイド腫瘍研究財団のような機関は、利害関係者を結束させ、治験治療への資金提供を加速させる上で重要な役割を果たしています。さらに、支払者制度や医療技術評価（HTA）機関は、特に強力な臨床試験データや希少疾病用医薬品に指定されている薬剤について、デスモイド腫瘍治療を償還の議論に含め始めています。

デスモイド腫瘍治療薬市場の成長を促すものは何か？

デスモイド腫瘍市場の成長は、治療法の革新、希少疾病用医薬品の開拓、診断能力の向上と密接に結びついたいくつかの要因によって牽引されています。第一に、β-カテニンやノッチシグナルなどの分子経路を標的とする精密治療薬の出現が臨床研究開発を活性化し、ニッチながんバイオテクノロジー企業からの投資を引き寄せています。ニロガセスタットのような治験薬の成功は、再利用されたがん治療薬と並んで、これまで侵襲的な手術や緩和ケアに限られていた患者の治療選択肢を広げています。

第二に、腫瘍センターにおけるゲノム検査の普及により、変異に基づく診断が改善され、デスモイド腫瘍の早期かつ正確な同定と治療法選択のための層別化が可能になりました。さらに、患者擁護団体や世界の希少疾病連合は、規制当局による承認の迅速化、コンパッショネートユースプログラムの拡大、償還経路の確保を求めるロビー活動に成功しています。希少がん登録や国際共同臨床試験にデスモイド腫瘍が組み入れられたことで、データ収集、認知度向上、臨床参加も促進されています。これらのダイナミクスは、有利な規制状況や高いアンメット・メディカル・ニーズと相まって、持続的な成長を促し、デスモイド腫瘍治療の商業的・臨床的展望を再構築しています。

セグメント

薬剤タイプ（非ステロイド性抗炎症薬、標的療法、化学療法、ホルモン療法、その他の薬剤タイプ）、流通チャネル（病院薬局、小売薬局、小売薬局）

調査対象企業の例（注目の43社）

  • 180 Life Sciences
  • AFT Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Ayala Pharmaceuticals
  • Bayer AG
  • Immunome, Inc.
  • Intas Pharmaceuticals
  • Iterion Therapeutics
  • Jina Pharmaceuticals
  • Johnson & Johnson
  • MedPact
  • Merck KGaA
  • Novartis
  • Pfizer
  • Recursion Pharmaceuticals, Inc.
  • Roche
  • SpringWorks Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Timber Pharmaceuticals

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33712

Global Desmoid Tumors Market to Reach US$8.0 Billion by 2030

The global market for Desmoid Tumors estimated at US$5.6 Billion in the year 2024, is expected to reach US$8.0 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Non-steroidal Anti-inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 7.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 9.9% CAGR

The Desmoid Tumors market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 9.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Desmoid Tumors Market - Key Trends & Drivers Summarized

What’s Fueling the Focus on Rare Tumors? A Strategic Look at the Desmoid Tumors Market

Desmoid tumors, also known as aggressive fibromatosis, are rare, non-metastasizing but locally invasive soft tissue tumors that present a complex clinical challenge due to their unpredictable progression and anatomical impact. Historically underdiagnosed and undertreated, this condition is now gaining renewed interest from both pharmaceutical innovators and clinical researchers due to advancements in genomic profiling and targeted therapies. One major trend reshaping the market is the identification of mutations in the CTNNB1 gene and the APC gene, which has opened the door to precision medicine approaches. These genetic markers allow stratification of patients for treatment responsiveness, particularly to Wnt/β-catenin signaling pathway inhibitors.

Another transformative trend is the shift away from surgery as the first line of treatment. Increasingly, physicians are adopting a “watchful waiting” strategy, supported by emerging data that many desmoid tumors stabilize or regress spontaneously. When intervention is necessary, non-surgical treatments including tyrosine kinase inhibitors (e.g., sorafenib) and gamma-secretase inhibitors (e.g., nirogacestat) are showing promising results. Regulatory momentum is also accelerating-U.S. FDA designations such as Orphan Drug Status and Fast Track designations for investigational therapies have attracted biotech investment into this rare disease space.

Why Is Treatment Modality Evolution So Critical in This Market?

The management paradigm for desmoid tumors is evolving rapidly, driven by the limitations of conventional surgery and radiotherapy, which carry high recurrence rates and morbidities. The newer treatment protocols are now favoring systemic therapies over localized interventions. Oral tyrosine kinase inhibitors (TKIs) like sorafenib, pazopanib, and imatinib are gaining traction for their non-invasive administration and relatively favorable safety profiles. These drugs inhibit angiogenesis and tumor proliferation pathways and have demonstrated effectiveness in delaying progression in unresectable cases.

Targeted therapies, particularly gamma-secretase inhibitors, represent a cutting-edge segment of the pipeline. SpringWorks Therapeutics' nirogacestat has emerged as a frontrunner after demonstrating statistically significant progression-free survival in phase III trials. These agents are poised to redefine standards of care as they interfere directly with the Notch signaling pathways implicated in tumor growth. Meanwhile, NSAIDs and hormonal therapies like tamoxifen continue to be used in select cases, particularly when systemic therapies are not tolerated. This therapeutic diversification is transforming the clinical outlook for desmoid tumor patients and expanding treatment options across disease stages and patient demographics.

Where Is Demand Emerging and Who Are the Key Stakeholders?

The desmoid tumor market is primarily concentrated in North America and Western Europe, where diagnostic infrastructure and rare disease research funding are most robust. However, rising awareness in emerging markets-particularly in urban hospital systems in Asia-Pacific and Latin America-is beginning to shift the global landscape. Diagnostic imaging improvements, increased physician education, and access to genomic testing are aiding earlier detection and more accurate classification of tumor subtypes.

Key stakeholders include academic research institutions, oncology-focused pharmaceutical companies, rare disease advocacy groups, and clinical trial networks. Patient registries and biobanking efforts are being expanded to better understand epidemiological patterns and treatment outcomes. Institutions like the Desmoid Tumor Research Foundation are playing a crucial role in uniting stakeholders and accelerating funding toward investigational therapies. Moreover, payer systems and health technology assessment (HTA) bodies are beginning to include desmoid tumor treatments in reimbursement discussions, especially for drugs with strong clinical trial data and orphan designations.

What’s Driving Growth in the Desmoid Tumors Therapeutics Market?

The growth in the desmoid tumors market is driven by several factors closely tied to therapeutic innovation, orphan drug development, and improved diagnostic capabilities. First, the emergence of precision therapies targeting molecular pathways such as β-catenin and Notch signaling has reinvigorated clinical R&D, attracting investment from niche oncology biotechs. The success of investigational therapies like nirogacestat, alongside repurposed oncology agents, is broadening treatment options for patients previously limited to invasive surgery or palliative care.

Second, the proliferation of genomic testing in oncology centers has improved mutation-based diagnosis, allowing earlier and more accurate identification of desmoid tumors and stratification for therapy selection. Moreover, patient advocacy and global rare disease coalitions are successfully lobbying for faster regulatory approvals, expanded compassionate use programs, and reimbursement pathways. The inclusion of desmoid tumors in rare cancer registries and global clinical trials is also boosting data collection, awareness, and clinical participation. These dynamics, combined with favorable regulatory designations and a high unmet medical need, are driving sustained growth and reshaping the commercial and clinical future of the desmoid tumor treatment landscape.

SCOPE OF STUDY:

The report analyzes the Desmoid Tumors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy, Other Drug Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Retail Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • 180 Life Sciences
  • AFT Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Ayala Pharmaceuticals
  • Bayer AG
  • Immunome, Inc.
  • Intas Pharmaceuticals
  • Iterion Therapeutics
  • Jina Pharmaceuticals
  • Johnson & Johnson
  • MedPact
  • Merck KGaA
  • Novartis
  • Pfizer
  • Recursion Pharmaceuticals, Inc.
  • Roche
  • SpringWorks Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Timber Pharmaceuticals

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Desmoid Tumors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Early Diagnosis of Rare Soft Tissue Tumors Expands Addressable Market for Desmoid Tumor Therapies
    • Increased Use of Imaging and Biopsy Tools Throws the Spotlight on Non-Invasive Diagnostic Advancements
    • Growing Pipeline of Targeted Therapies and Small Molecule Inhibitors Drives Innovation in Desmoid Tumor Management
    • Regulatory Approvals and Orphan Drug Designations Propel Investment in Desmoid Tumor Drug Development
    • Expansion of Clinical Trials Focused on Gamma Secretase Inhibitors Spurs Momentum in Targeted Treatment Options
    • Growing Role of Multidisciplinary Tumor Boards Strengthens Business Case for Personalized Therapy Strategies
    • Shift Toward Active Surveillance and Conservative Management in Select Cases Challenges Pharmaceutical Demand
    • Increased Genetic Screening for APC and CTNNB1 Mutations Enhances Precision Diagnosis and Therapeutic Targeting
    • AI-Enabled Diagnostic Imaging Tools Support Accurate and Early Detection, Expanding Treatment Opportunities
    • Rising Demand for Non-Surgical Therapies Spurs Adoption of Systemic and Minimally Invasive Options
    • Increased Incidence of Sporadic Desmoid Tumors in Younger Adults Expands Long-Term Treatment Horizons
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Desmoid Tumors Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Desmoid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Non-steroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Non-steroidal Anti-inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Non-steroidal Anti-inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Desmoid Tumors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Desmoid Tumors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Desmoid Tumors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Desmoid Tumors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Desmoid Tumors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Desmoid Tumors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Desmoid Tumors by Drug Type - Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Desmoid Tumors by Drug Type - Percentage Breakdown of Value Sales for Non-steroidal Anti-inflammatory Drugs, Targeted Therapy, Chemotherapy, Hormone Therapy and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Desmoid Tumors by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Desmoid Tumors by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION